Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CCR1 | P32246 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 3/20 | 0.48 |
| ▸ | CCR8 | P51685 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901314 | 0.87 | CA12 (0.47) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL26527466 | 0.83 | CA12 (0.49) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL1314692 | 0.83 | NOTUM (0.62) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL31434715 | 0.83 | NOTUM (0.62) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL8938531 | 0.83 | CA12 (0.49) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL2120922 | 0.83 | NOTUM (0.62) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL15399007 | 0.80 | NOTUM (0.37) | CA12CA9LMNAPOLBSMN1; SMN2 | |
| SCHEMBL9902305 | 0.80 | CA12 (0.47) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL15142095 | 0.79 | CA12 (0.46) | CA12CA9KDM4ELMNACCR1 | |
| SCHEMBL6705331 | 0.79 | CA12 (0.49) | CA12CA9KDM4ELMNACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3 2 PHARMA LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA, LLC | 2021-10-14 | — | — | US | disclosed |
| WO-2021183796-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | 3+2 PHARMA (US) | 2021-09-16 | — | — | WO | disclosed |
| EP-3216798-A2 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2017-09-13 | — | — | EP | disclosed |
| EP-3216798-A2 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2017-09-13 | — | — | EP | disclosed |
| EP-2673285-B1 | KETOLIDE COMPOUNDS | WOCKHARDT LTD (IN) | 2017-07-19 | — | — | EP | disclosed |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| US-9175031-B2 | Ketolide compounds | WOCKHARDT LIMITED (IN) | 2015-11-03 | — | — | US | disclosed |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-01-02 | — | — | US | disclosed |
| EP-2673285-A1 | KETOLIDE COMPOUNDS | Wockhardt Limited (IN) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012076989-A1 | KETOLIDE COMPOUNDS | WOCKHARDT LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348476-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | CA12 4434/4885CA9 2858/4885KDM4E 773/4885 |
| US-11655253-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, EP300 | CA12 4434/4885CA9 2858/4885KDM4E 773/4885 |
| US-20160083412-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | CA12 2670/4885CA9 518/4885KDM4E 313/4885 |
| US-20140005133-A1 | KETOLIDE COMPOUNDS | AKR1C3, AKR1D1, AKR1C1 | CA12 2342/4885CA9 428/4885KDM4E 298/4885 |
| US-20210317123-A1 | CBP/CATENIN SIGNALING PATHWAY INHIBITORS AND USES THEREOF | CREBBP, CREB1, EP300 | CA12 4434/4885CA9 2858/4885KDM4E 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.